Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emil Kuriakose

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Haematologica|November 22, 2011
Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia veraEmil Kuriakose, Katherine Vandris, Y Lynn Wang, et al.
BMJ Oncology|January 31, 2025
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumoursAung Naing, Kyriakos P Papadopoulos, Michael J Pishvaian, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful EngraftmentUsama Gergis, Emil Kuriakose, Tsiporah Shore, et al.
Cancer Research|August 24, 2018
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Haematologica|November 22, 2011
Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia veraEmil Kuriakose, Katherine Vandris, Y Lynn Wang, et al.
BMJ Oncology|January 31, 2025
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumoursAung Naing, Kyriakos P Papadopoulos, Michael J Pishvaian, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful EngraftmentUsama Gergis, Emil Kuriakose, Tsiporah Shore, et al.
Cancer Research|August 24, 2018
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, et al.
Pageof 1